Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Satralizumab may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Enspryng is Enspryng contains the active substance satralizumab. It is a type of protein called a monoclonal antibody. Monoclonal antibodies are designed to recognise and attach to a specific substance in the body. What Enspryng is used for Enspryng is a medicine for treating neuromyelitis optica spectrum disorders (NMOSD) in adults and young people from 12 years of age. What is NMOSD NMOSD is a disease of the central nervous system that mainly affects the optic nerves and spinal cord. It is caused by the immune system (the body's defences) working incorrectly and attacking nerves in the body.
1 uk-pil-enspryng-clean-260429-120mg-pfs
How Enspryng works Enspryng blocks the action of a protein called interleukin-6 (IL-6), which is involved in the processes that lead to damage and swelling in the nervous system. By blocking its effects, Enspryng reduces the risk of a relapse or attack of NMOSD. 2.
e Enspryng
Do not use Enspryng
•
abdominal pain
White blood cell count Your doctor will perform blood tests before you are given Enspryng, and during your treatment, to check your white blood cell count. Children and young people Do not give this medicine to children under 12 years of age. This is because it has not yet been studied in this age group. Other medicines and Enspryng Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Tell your doctor or pharmacist if you are taking medicines such as warfarin, carbamazepine, phenytoin and theophylline as doses might need to be adjusted. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor may advise you to stop breast-feeding if you are to be given Enspryng. It is not known whether Enspryng passes into breast milk. Driving and using machines Enspryng is not likely to affect you being able to drive, cycle or use any tools or machines. 3.
How to use Enspryng
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. How much Enspryng to use Each injection contains 120 mg of satralizumab. The first injection will be given under the supervision of your doctor or nurse.
Enspryng
3 uk-pil-enspryng-clean-260429-120mg-pfs
If you accidentally inject more doses than you should, call your doctor. Always take the outer carton with you when you go to see the doctor. If you forget to use Enspryng For the treatment to be fully effective, it is very important to keep having the injections. If your doctor or nurse is giving your injections and you miss an appointment, make another one straight away. If you are injecting Enspryng yourself and you miss an injection, inject it as soon as possible. Do not wait until the next planned dose. After you have had the injection for the missed dose, your next injection should be either:
Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions Tell your doctor straight away or go to the emergency department of your nearest hospital, if you have any signs of allergic reactions during or after the injection. They include:
Other side effects: Very common (may affect more than 1 in 10 people)
Enspryng
5 uk-pil-enspryng-clean-260429-120mg-pfs
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Enspryng contains
6 uk-pil-enspryng-clean-260429-120mg-pfs
Instructions for use Read these instructions for use:
Supplies needed to give your injection Each Enspryng carton contains:
• • • •
1 alcohol pad 1 sterile cotton ball or gauze 1 small bandage 1 puncture-resistant sharps container for safe disposal of the needle cap and used syringe. See step 21 "Disposing of Enspryng" at the end of these instructions for use.
7 uk-pil-enspryng-clean-260429-120mg-pfs
Enspryng pre-filled syringe (See Figure A and Figure B) Before use: Activation guards (Do not touch)
Barrel
Needle cap
Expiry date
Plunger
Figure A After use:
Automatic needle-guard (extended and locked)
Figure B The syringe has an automatic needle-guard that covers the needle when the injection is complete.
Prepare to use Enspryng 1. Take the carton containing the syringe out of the refrigerator and place it on a clean, flat work surface (like a table). 2. Check the expiry date on the back of the carton (see Figure C). Do not use if the carton has expired. 3. Check that the front of the carton is sealed (see Figure C). Do not use if the seal is broken. If the expiry date has passed or the seal is broken, go to step 21 "Disposing of Enspryng" and contact your doctor or nurse.
Figure C
8 uk-pil-enspryng-clean-260429-120mg-pfs
4. Open the sealed carton (see Figure D).
Figure D 5. Carefully lift the syringe out of the carton by holding the barrel (see Figure E).
Figure E Check the syringe (See Figure F) 6. Check the expiry date on the syringe. Do not use the syringe if it has expired. 7. Check the syringe for any damage. Do not use if it is cracked or broken. 8. Check that the liquid through the viewing window is clear and colourless to slightly yellow. Do not inject the medicine if the liquid is cloudy, discoloured, or has particles in it.
Figure F If the expiry date has passed, the syringe is damaged or the liquid is cloudy, discoloured or has particles in it, do not use. Then go to step 21 "Disposing of Enspryng" and contact your doctor or nurse.
9 uk-pil-enspryng-clean-260429-120mg-pfs
Let your syringe get to room temperature 9. Once you have checked the syringe, place it on a clean, flat work surface (like a table) for 30 minutes. This will allow it to reach room temperature (see Figure G). It is important to let the syringe gently reach room temperature because injecting cold medicine may feel uncomfortable and make it harder to push the plunger.
Figure G Wash your hands 10. Wash your hands with soap and water (see Figure H).
Figure H Choose the injection site 11. Choose your injection site in either:
Injection site areas
Figure I
10 uk-pil-enspryng-clean-260429-120mg-pfs
• •
Do not fan or blow on the area which you have cleaned. Do not touch the injection site again before you give the injection.
Figure J Inject Enspryng 13. Hold the barrel of the syringe between your thumb and index finger. With your other hand, pull the needle cap straight off. You may see a drop of liquid at the end of the needle. This is normal and will not affect your dose (see Figure K).
Figure K 14. Throw away the needle cap in a puncture-resistant sharps container immediately. See step 21 "Disposing of Enspryng". 15. Hold the barrel of the syringe using your thumb and index finger. With your other hand, pinch the area of skin you have cleaned (see Figure L). 16. Use a quick, dart-like motion to insert the needle at an angle between 45° to 90° (see Figure L).
Figure L 17. After the needle is inserted, let go of the pinched skin.
11 uk-pil-enspryng-clean-260429-120mg-pfs
18. Slowly inject all of the medicine by gently pushing the plunger all the way down until it touches the activation guards (see Figure M).
Figure M 19. Gently release the plunger and allow the needle to come out of the skin at the same angle it was inserted (see Figure N).
•
Figure N The needle will now be covered by the automatic needle-guard. If the needle is not covered, carefully place the syringe into a puncture-resistant sharps container to avoid injury. See step 21 "Disposing of Enspryng".
Taking care of the injection site 20. There may be a little bleeding at the injection site. You can press a cotton ball or gauze over the injection site until any bleeding stops but do not rub it. If needed, you may also cover the area you injected with a small bandage. If the medicine comes into contact with your skin, wash the area with water. Disposing of Enspryng 21. Do not try to re-cap your syringe. Put your used syringe in a sharps disposal container immediately after use (see Figure O). Do not throw the syringe in your household waste and do not recycle it.
• • • •
Figure O Ask your doctor or nurse or pharmacist for information about where you can get a "sharps" container or what other types of puncture-resistant containers you can use to safely dispose of your used syringes and needle caps. Dispose of the used sharps disposal container as instructed by your healthcare provider or pharmacist. Do not dispose of your used sharps disposal container in your household waste. Do not recycle your used sharps disposal container. 12 uk-pil-enspryng-clean-260429-120mg-pfs
Enspryng 120 mg solution for injection in pre-filled syringe comes as injection containing 120mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Enspryng 120 mg solution for injection in pre-filled syringe is satralizumab.
This leaflet reproduces the patient information leaflet approved for Enspryng 120 mg solution for injection in pre-filled syringe, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Enspryng is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive (see section 5.1).
Treatment should be initiated under the supervision of a physician experienced in the treatment of neuromyelitis optica (NMO) or NMOSD.
Posology
Enspryng can be used as a monotherapy or in combination with oral corticosteroids (OCs), azathioprine (AZA) or mycophenolate mofetil (MMF) (see section 5.1). The posology in adolescent patients ≥12 years of age with body weight ≥ 40 kg and adult patients is the same.
Loading doses
The recommended loading dose is 120 mg subcutaneous injection every two weeks for the first three administrations (first dose at week 0, second dose at week 2 and third dose at week 4).
Maintenance doses
The recommended maintenance dose is 120 mg subcutaneous injection every four weeks.
Duration of treatment
Enspryng is intended for long-term treatment.
Delayed or missed doses
If an injection is missed, for any reason other than increases in liver enzymes, it should be administered as described in table 1.
Table 1: Recommended dose for delayed or missed doses
Last dose administered
Recommended dose for delayed or missed doses
Missed a loading dose or less than 8 weeks during the maintenance period
The recommended dose should be administered as soon as possible without waiting until the next planned dose.
Loading period
If the second loading dose is delayed or missed, this dose should be administered as soon as possible and the third and final loading dose 2 weeks later.
If the third loading dose is delayed or missed, this dose should be administered as soon as possible and the first maintenance dose 4 weeks later.
Maintenance period
After the delayed or missed dose is administered, the dosing schedule should be reset to every 4 weeks.
8 weeks to less than 12 weeks
The recommended dose should be administered at 0*, 2 weeks and every 4 weeks thereafter.
12 weeks or longer
The recommended dose should be administered at 0*, 2, 4 weeks and every 4 weeks thereafter.
* “0 weeks” refers to time of the first administration after the missed dose.
Dose modification advice for liver enzyme abnormalities
If the alanine aminotransferase (ALT) or aspartate transaminase (AST) elevation is >5 x upper limit of normal (ULN) and associated with any bilirubin elevation, treatment must be discontinued, and reinitiation is not recommended.
If the ALT or AST elevation is >5 x ULN and not associated with any bilirubin elevation, treatment should be discontinued. Treatment can be restarted at a dose of 120 mg subcutaneous injection every four weeks when the ALT and AST levels have returned to the normal range and based on assessment of benefit-risk of treatment in the patient. If the decision is taken to restart treatment, liver parameters must be closely monitored, and if any subsequent increase in ALT/AST and/or bilirubin is observed, treatment must be discontinued, and reinitiation is not recommended (see sections 4.4 and 4.8).
Table 2: Recommended dose for restart of treatment after liver transaminase elevation
Last dose administered
Recommended dose for restart of treatment
Less than 12 weeks
Treatment should be restarted using the recommended dose, given every 4 weeks.
12 weeks or longer
Treatment should be restarted using the recommended dose, given at weeks 0*, 2, 4 and every 4 weeks thereafter.
* “0 weeks” refers to time of the first administration after the restart of treatment.
Dose modification advice for neutropenia
If the neutrophil count is below 1.0 x 109/L and confirmed by repeat testing, treatment should be interrupted until the neutrophil count is >1.0 x 109/L.
Dose modification advice for low platelet count
If the platelet count is below 75 x 109/L and confirmed by repeat testing, treatment should be interrupted until the platelet count is ≥75 x 109/L.
Special populations
Paediatric population
The posology in adolescent patients ≥12 years of age with body weight ≥ 40 kg and adult patients is the same (see sections 5.1 and 5.2). The safety and efficacy of satralizumab in children with body weight < 40 kg have not yet been established. No data are available.
Elderly
No dose adjustment is required in patients ≥65 years of age (see section 5.2).
Renal impairment
The safety and efficacy of satralizumab have not been formally studied in patients with renal impairment. No dose adjustment is recommended for patients with mild renal impairment (see section 5.2).
Hepatic impairment
The safety and efficacy of satralizumab have not been studied in patients with hepatic impairment. No data are available (see section 5.2).
Elevations of liver enzymes have been observed during treatment with satralizumab (see sections 4.4 and 4.8). For dose adjustment, see above section Dose modification advice for liver enzyme abnormalities.
Method of administration
Satralizumab 120 mg is administered by subcutaneous injection using a single-dose pre-filled syringe. The total content (1 mL) of the pre-filled syringe should be administered.
The recommended injection sites are the abdomen and thigh. Injection sites should be rotated and injections should never be given into moles, scars, or areas where the skin is tender, bruised, red, hard, or not intact.
Comprehensive instructions for the administration of satralizumab are given at the end of the package leaflet.
Administration by the patient and/or caregiver
The first injection must be performed under the supervision of a qualified Healthcare Professional (HCP).
After adequate training on how to prepare and perform the injection, an adult patient/caregiver may administer all other doses at home if the treating physician determines that it is appropriate and the adult patient/caregiver can perform the injection technique.
Patients/caregivers should seek immediate medical attention if the patient develops symptoms of serious allergic reactions and should check with their HCP to confirm whether treatment can be continued or not.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Traceability
In order to improve traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Infections
Administration of satralizumab should be delayed in patients with an active infection until the infection is controlled (see section 4.2).
Vigilance for the timely detection and diagnosis of infection is recommended for patients receiving treatment with satralizumab. Treatment should be delayed in case the patient develops any serious or opportunistic infection and appropriate therapy should be initiated under further monitoring. Patients should be instructed on seeking early medical attention in case of signs and symptoms of infections to facilitate timely diagnosis of infections. Patients should be provided with a patient alert card.
Vaccinations
Live and live-attenuated vaccines should not be given concurrently with satralizumab as clinical safety has not been established. The interval between live vaccinations and initiation of satralizumab treatment should be in accordance with current vaccination guidelines regarding immunomodulatory or immunosuppressive agents.
No data are available on the effects of vaccination in patients receiving satralizumab. It is recommended that all patients be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating satralizumab treatment.
Liver enzymes
Mild and moderate elevations of liver transaminases have been observed with satralizumab treatment, most elevations were below 5 x ULN (see section 4.8).
ALT and AST levels should be monitored every four weeks for the first three months of treatment, followed by every three months for one year, thereafter as clinically indicated.
Treatment with satralizumab should be discontinued in patients with ALT or AST >5 x ULN (see section 4.2).
Neutrophil count
Decreases in neutrophil counts have occurred following treatment with satralizumab (see section 4.8). Neutrophil counts should be monitored 4 to 8 weeks after start of treatment and thereafter as clinically indicated. For recommended dose interruption see section 4.2.
No interaction studies have been performed.
Population pharmacokinetic (PK) analyses did not detect any effect of azathioprine (AZA), oral corticosteroids (OCs) or mycophenolate mofetil (MMF) on the clearance of satralizumab.
Both in vitro and in vivo studies have shown that the expression of specific hepatic CYP450 enzymes (CYP1A2, CYP2C9, CYP2C19, and CYP3A4) is suppressed by cytokines such as IL-6.
Therefore caution should be exercised when starting or discontinuing satralizumab treatment in patients also receiving substrates of CYP450 3A4, 1A2, 2C9 or 2C19, particularly those with a narrow therapeutic index (such as warfarin, carbamazepine, phenytoin and theophylline), and doses adjusted if needed.
Given the prolonged terminal half-life of satralizumab, the effect of satralizumab may persist for several weeks after stopping treatment.
Pregnancy
There are no data from the use of satralizumab in pregnant women. Studies in monkeys do not indicate harmful effects with respect to reproductive toxicity (see section 5.3).
As a precautionary measure, it is preferable to avoid the use of Enspryng during pregnancy.
Breast-feeding
It is unknown whether satralizumab is excreted in human breast milk. Human IgG is known to be excreted in breast milk during the first days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to breast-fed infants cannot be excluded during this short period. Afterwards, use of Enspryng could be considered during breast-feeding only if clinically needed.
Fertility
No clinical data are available on the effect of satralizumab on human fertility. Animal studies showed no impairment of male or female fertility (see section 5.3).
Enspryng has no or negligible influence on the ability to drive and use machines.
Summary of the safety profile
The most frequently reported adverse reactions observed were: headache (19.2%), arthralgia (13.5%), white blood cell count decreased (13.5%), hyperlipidaemia (13.5%), and injection-related reactions (12.5%).
Tabulated list of adverse reactions
Table 3 summarises the adverse reactions that have been reported in association with the use of satralizumab as a monotherapy or in combination with IST in clinical trials.
Adverse reactions from clinical trials (Table 3) are listed by MedDRA system organ class. Adverse reactions are presented using number of adverse events per 100 patient years and by frequency figures. The corresponding frequency category for each adverse reaction is based on frequency figures and the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Table 3: Adverse reactions
System Organ Class
Frequency
Very common
Common
Blood and lymphatic system disorders
Hypofibrinogenaemia
Metabolism and nutrition disorders
Hyperlipidaemia
Psychiatric disorders
Insomnia
Nervous system disorders
Headache
Migraine
Cardiac disorders
Bradycardia
Vascular disorders
Hypertension
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
Gastrointestinal disorders
Gastritis
Skin and subcutaneous tissue disorders
Rash,
pruritus
Musculoskeletal and connective tissue disorders
Arthralgia
Musculoskeletal stiffness
General disorders and administration site conditions
Injection-related reactions
Peripheral oedema
Investigations
White blood cell count decreased
Neutrophil count decreased
platelet count decreased,
transaminases increased,
blood bilirubin increased, weight increased
Description of selected adverse reactions
Injection-related reactions (IRRs)
IRRs reported in patients treated with satralizumab were predominantly mild to moderate, and most occurred within 24 hours after injections. The most commonly reported systemic symptoms were diarrhoea and headache. The most commonly reported local injection site reactions were flushing, erythema, pruritus, rash and pain.
Body weight
In the double-blinded treatment period, body weight increase ≥15% from baseline were observed in 3.8% of patients treated with satralizumab (monotherapy or in combination with IST) as compared with 2.7% of patients receiving placebo (or plus IST).
Laboratory abnormalities
Neutrophils
In the double-blinded treatment period, decreased neutrophils were observed in 31.7% of patients treated with satralizumab (monotherapy or in combination with IST) as compared with 21.6% of patients receiving placebo (or placebo plus IST). The majority of neutrophil decreases were transient or intermittent.
9.6% of patients receiving satralizumab had neutrophils below 1 x 109/L, compared with 5.4% receiving placebo (or placebo plus IST).
Platelets
In the double-blinded treatment period, decreases in platelet count (below 150 × 109/l) occurred in 24.0% of patients on satralizumab (monotherapy or in combination with IST) as compared with 9.5% of patients receiving placebo or placebo plus IST. The decreased platelet count was not associated with bleeding events.
The majority of the decreased platelets were transient and not below 75 × 109/l.
Liver enzymes
In the double-blinded treatment period, elevations in ALT or AST occurred in 27.9% and 18.3% of patients treated with satralizumab (monotherapy or in combination with IST) respectively, compared with 12.2% and 13.5% of patients receiving placebo or placebo plus IST. The majority of the elevations were below 3 x ULN, were transient and resolved without interruption of satralizumab.
Elevations in ALT or AST >3 x ULN occurred in 2.9% and 1.9% of patients treated with satralizumab (monotherapy or in combination with IST) respectively. These elevations were not associated with increases in total bilirubin.
Elevations of ALT above 5 x ULN were observed 4 weeks after initiation of therapy in one (1%) patient receiving satralizumab in combination with IST; normalising after discontinuation of treatment, and satralizumab was not reintroduced in this patient (see sections 4.2 and 4.4).
Lipid parameters
In the double-blinded treatment period, 10.6% of patients receiving satralizumab (monotherapy or in combination with IST) experienced elevations in total cholesterol above 7.75 mmol/l as compared with 1.4% of patients receiving placebo (or placebo plus IST); 20.2% of patients receiving satralizumab experienced elevations in triglycerides above 3.42 mmol/l as compared with 10.8% of patients receiving placebo.
Paediatric population
The safety and efficacy of satralizumab have been studied in 9 children ≥12 years of age. Frequency, type and severity of adverse reactions in children from 12 years of age are expected to be the same as in adults.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
In the event of an overdose, the patient should be closely supervised, treated symptomatically, and supportive measures instituted as required.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Enspryng 120 mg solution for injection in pre-filled syringe. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.